For outsourcing facilities under section 503B of the FD&C Act, until May 22, 2025, or until the date of the district courts decision on the plaintiffs forthcoming preliminary injunction motion in OFA v
The following adverse events, use methods other than those described on the label, abdominal distension, belching, and improper product handling time, are more commonly observed in subcutaneous injection
This creates a larger energy deficit
Vision Changes Some people with diabetes have reported worsening diabetic retinopathy when starting incretin medications, possibly related to rapid blood sugar improvement
The opinions go from "Hims & Hers is doomed" over "a typical fight between an incumbent and an innovator" to "Hims & Hers should sue Novo Nordisk for defamation." Let's be clear upfront